PURPOSE: To investigate the feasibility of longitudinal assessment of functional performance measures in newly diagnosed postsurgical malignant glioma patients. METHODS: Patients with histologically confirmed, clinically stable, postsurgical, and previously untreated high-grade glioma (HGG) or low-grade glioma (LGG) were studied. Using a prospective design, all participants performed a cardiopulmonary exercise test with expired gas analysis to assess cardiorespiratory function (VO(2peak)) immediately following surgical resection (mean, 10 days). Additional functional outcomes were skeletal muscle cross-sectional area (CSA) via magnetic resonance imaging, isokinetic muscle strength (isokinetic dynamometry), and body composition (air displacement plethysmography). Quality of life (QOL) was assessed by the Functional Assessment of Cancer Therapy-Brain scale. All study assessments were repeated at 6 and 24 weeks following surgery. RESULTS: Thirty-five patients (HGG, n = 25; LGG, n = 10) completed baseline assessments. Of these, 20 HGG (80%) and nine LGG (90%) and 15 HGG (60%) and nine LGG (90%) patients completed study assessments at 6 weeks and 24 weeks, respectively. Intention-to-treat analyses indicated several significant time-by-group interactions, with favorable improvements in functional and QOL endpoints from baseline to 24 weeks in the LGG cohort and unfavorable changes in the HGG cohort. Per-protocol analyses including participants assessed at all three study timepoints indicated significant improvements in VO(2peak) and fatigue from baseline to 24 weeks in the HGG cohort; peak workload, body composition, and muscle strength improved from baseline to 6 weeks (all p-values < .05). CONCLUSIONS: Longitudinal quantitative functional assessments are safe and feasible among select patients undergoing chemoradiation for primary malignant glioma. Large prospective studies investigating the clinical importance of these measures appear warranted.
PURPOSE: To investigate the feasibility of longitudinal assessment of functional performance measures in newly diagnosed postsurgical malignant gliomapatients. METHODS:Patients with histologically confirmed, clinically stable, postsurgical, and previously untreated high-grade glioma (HGG) or low-grade glioma (LGG) were studied. Using a prospective design, all participants performed a cardiopulmonary exercise test with expired gas analysis to assess cardiorespiratory function (VO(2peak)) immediately following surgical resection (mean, 10 days). Additional functional outcomes were skeletal muscle cross-sectional area (CSA) via magnetic resonance imaging, isokinetic muscle strength (isokinetic dynamometry), and body composition (air displacement plethysmography). Quality of life (QOL) was assessed by the Functional Assessment of Cancer Therapy-Brain scale. All study assessments were repeated at 6 and 24 weeks following surgery. RESULTS: Thirty-five patients (HGG, n = 25; LGG, n = 10) completed baseline assessments. Of these, 20 HGG (80%) and nine LGG (90%) and 15 HGG (60%) and nine LGG (90%) patients completed study assessments at 6 weeks and 24 weeks, respectively. Intention-to-treat analyses indicated several significant time-by-group interactions, with favorable improvements in functional and QOL endpoints from baseline to 24 weeks in the LGG cohort and unfavorable changes in the HGG cohort. Per-protocol analyses including participants assessed at all three study timepoints indicated significant improvements in VO(2peak) and fatigue from baseline to 24 weeks in the HGG cohort; peak workload, body composition, and muscle strength improved from baseline to 6 weeks (all p-values < .05). CONCLUSIONS: Longitudinal quantitative functional assessments are safe and feasible among select patients undergoing chemoradiation for primary malignant glioma. Large prospective studies investigating the clinical importance of these measures appear warranted.
Authors: Lee W Jones; Neil D Eves; John R Mackey; Carolyn J Peddle; Mark Haykowsky; Anil A Joy; Kerry S Courneya; Keith Tankel; Jennifer Spratlin; Tony Reiman Journal: Lung Cancer Date: 2006-11-17 Impact factor: 5.705
Authors: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman Journal: J Neurooncol Date: 2009-02-11 Impact factor: 4.130
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Amy P Abernethy; Tania Shelby-James; Belinda S Fazekas; David Woods; David C Currow Journal: BMC Palliat Care Date: 2005-11-12 Impact factor: 3.234
Authors: Mohammad Keilani; Christoph Krall; Christine Marosi; Birgit Flechl; Karin Dieckmann; Georg Widhalm; Maximilian Marhold; Richard Crevenna Journal: Wien Klin Wochenschr Date: 2012-06-12 Impact factor: 1.704
Authors: S Nicole Culos-Reed; Heather J Leach; Lauren C Capozzi; Jacob Easaw; Neil Eves; Guillaume Y Millet Journal: Support Care Cancer Date: 2016-12-17 Impact factor: 3.603
Authors: Lee W Jones; Francis Ali-Osman; Eric Lipp; Jennifer E Marcello; Bridget McCarthy; Lucie McCoy; Terri Rice; Margaret Wrensch; Dora Il'yasova Journal: Cancer Causes Control Date: 2010-09-14 Impact factor: 2.506
Authors: Emily Ruden; David A Reardon; April D Coan; James E Herndon; Whitney E Hornsby; Miranda West; Diane R Fels; Annick Desjardins; James J Vredenburgh; Emily Waner; Allan H Friedman; Henry S Friedman; Katherine B Peters; Lee W Jones Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: Ali Dulfikar; Eng-Siew Koh; Zarnie Lwin; Elizabeth Hovey; Haryana Dhillon; Jesica Arundell; Elizabeth Pinkham; Mark B Pinkham; Justin Holland; Gabriel Trajano; Fiona Naumann Journal: Neurooncol Pract Date: 2021-02-22
Authors: Favil Singh; Robert U Newton; Michael K Baker; Nigel A Spry; Dennis R Taaffe; Jeffery Thavaseelan; Daniel A Galvão Journal: Integr Cancer Ther Date: 2016-09-01 Impact factor: 3.279
Authors: Ellen M P van Coevorden-van Loon; Marijke B Coomans; Majanka H Heijenbrok-Kal; Gerard M Ribbers; Martin J van den Bent Journal: J Neurooncol Date: 2017-05-24 Impact factor: 4.130